SCHEMBL20652969

SCHEMBL20652969

Cn1c(=O)[nH]c(=O)c2[nH]c(-c3nccnc3Cl)nc21

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 3/20 0.47
▸ ALDH1A1 P00352 2/20 0.47
▸ SMN1; SMN2 Q16637 2/20 0.47
▸ KDM4E B2RXH2 2/20 0.47
▸ GLA P06280 1/20 0.47
▸ CASP1 P29466 1/20 0.47
▸ CASP7 P55210 1/20 0.47
▸ HSD17B10 Q99714 1/20 0.47
▸ RXFP1 Q9HBX9 1/20 0.43
▸ GAA P10253 3/20 0.41
▸ MAPT P10636 2/20 0.41
▸ MAPK1 P28482 2/20 0.41
▸ TP53 P04637 1/20 0.41
▸ TSHR P16473 1/20 0.41
▸ XBP1 P17861 1/20 0.41
▸ ATM Q13315 1/20 0.41
▸ NPSR1 Q6W5P4 1/20 0.41
▸ MEN1 O00255 1/20 0.39
▸ LMNA P02545 1/20 0.39
▸ PABPC1 P11940 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20652782 0.83 ADORA2A (0.34) KMT2AALDH1A1SMN1; SMN2KDM4EGLA
SCHEMBL20652758 0.83 ADORA2A (0.49) KMT2AALDH1A1SMN1; SMN2KDM4EGLA
SCHEMBL3563144 0.73 ALDH1A1 (0.49) KMT2AALDH1A1SMN1; SMN2KDM4EGLA
SCHEMBL6889649 0.71 ADORA2B (0.69) KMT2AALDH1A1SMN1; SMN2KDM4EGLA
SCHEMBL1497239 0.69 ALDH1A1 (0.49) KMT2AALDH1A1SMN1; SMN2KDM4EGLA
SCHEMBL387339 0.68 ALDH1A1 (0.54) KMT2AALDH1A1SMN1; SMN2KDM4EGLA
SCHEMBL20656214 0.68 KDM4E (0.53) KMT2AALDH1A1SMN1; SMN2KDM4EGLA
SCHEMBL20652970 0.67 ATM (0.62) KMT2AALDH1A1GLAHSD17B10GAA
SCHEMBL1241218 0.66 ALDH1A1 (0.49) KMT2AALDH1A1SMN1; SMN2KDM4EGLA
SCHEMBL6890038 0.66 CHRNB2 (0.53) KMT2AALDH1A1SMN1; SMN2KDM4EGLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3652176-B1 SUBSTITUTED XANTHINE DERIVATIVES BOEHRINGER INGELHEIM INT (DE) 2021-12-15 — — EP disclosed
US-10329292-B2 Substituted xanthine derivatives BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2019-06-25 — — US disclosed
WO-2019011802-A1 NOVEL SUBSTITUTED XANTHINE DERIVATIVES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2019-01-17 — — WO disclosed
US-20190016722-A1 NOVEL SUBSTITUTED XANTHINE DERIVATIVES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2019-01-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10329292-B2 Substituted xanthine derivatives TRPC5, TRPV1, TRPC4 KMT2A 4180/4885ALDH1A1 1347/4885SMN1; SMN2 1063/4885
US-20190016722-A1 NOVEL SUBSTITUTED XANTHINE DERIVATIVES TRPC5, TRPC4, TRPV1 KMT2A 4155/4885ALDH1A1 1488/4885SMN1; SMN2 1361/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback